Market Research Logo

Non-Small Cell Lung Cancer - Pipeline Review, H1 2018

Non-Small Cell Lung Cancer - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Small Cell Lung Cancer - Pipeline Review, H1 2018, provides an overview of the Non-Small Cell Lung Cancer (Oncology) pipeline landscape.

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in later stages of the disease. The signs and symptoms include persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody phlegm or spit (sputum), fatigue and weakness and unintentional weight loss. The disease might be controlled with the help of medications, chemotherapy and modifications in lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Small Cell Lung Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Small Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Small Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 9, 1, 49, 238, 205, 16, 175, 30 and 14 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 13, 14, 46 and 5 molecules, respectively.

Non-Small Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Non-Small Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Non-Small Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Non-Small Cell Lung Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Non-Small Cell Lung Cancer - Overview
Non-Small Cell Lung Cancer - Therapeutics Development
Non-Small Cell Lung Cancer - Therapeutics Assessment
Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development
Non-Small Cell Lung Cancer - Drug Profiles
Non-Small Cell Lung Cancer - Dormant Projects
Non-Small Cell Lung Cancer - Discontinued Products
Non-Small Cell Lung Cancer - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Non-Small Cell Lung Cancer, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Non-Small Cell Lung Cancer - Pipeline by 3-V Biosciences Inc, H1 2018
Non-Small Cell Lung Cancer - Pipeline by 3SBio Inc, H1 2018
Non-Small Cell Lung Cancer - Pipeline by 4D Pharma PLC, H1 2018
Non-Small Cell Lung Cancer - Pipeline by 4SC AG, H1 2018
Non-Small Cell Lung Cancer - Pipeline by AbbVie Inc, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Ability Pharmaceuticals SL, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Abpro, H1 2018
Non-Small Cell Lung Cancer - Pipeline by ACEA Biosciences Inc, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Adamed Sp z oo, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Aduro BioTech Inc, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Advantagene Inc, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Advaxis Inc, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Advenchen Laboratories LLC, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Agenus Inc, H1 2018
Non-Small Cell Lung Cancer - Pipeline by AlfaSigma SpA, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Altimmune Inc, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Altor BioScience Corp, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Amgen Inc, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Andarix Pharmaceuticals Inc, H1 2018
Non-Small Cell Lung Cancer - Pipeline by AndroScience Corp, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Apexigen Inc, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Aptose Biosciences Inc, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Arcus Biosciences Inc, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Ariad Pharmaceuticals Inc, H1 2018
Non-Small Cell Lung Cancer - Pipeline by ARMO Biosciences Inc, H1 2018
Non-Small Cell Lung Cancer - Pipeline by ArQule Inc, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Array BioPharma Inc, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Asana BioSciences LLC, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Ascentage Pharma Group Corp Ltd, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Astellas Pharma Inc, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Asterias Biotherapeutics Inc, H1 2018
Non-Small Cell Lung Cancer - Pipeline by AstraZeneca Plc, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Atreca Inc, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Aurobindo Pharma Ltd, H1 2018
Non-Small Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Basilea Pharmaceutica Ltd, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Batu Biologics Inc, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Bavarian Nordic A/S, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Bayer AG, H1 2018
Non-Small Cell Lung Cancer - Pipeline by BeiGene Ltd, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H1 2018
Non-Small Cell Lung Cancer - Pipeline by BerGenBio ASA, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Beta Pharma Inc, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Betta Pharmaceuticals Co Ltd, H1 2018
Non-Small Cell Lung Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Bicycle Therapeutics Ltd, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Bio-Cancer Treatment International Ltd, H1 2018
Non-Small Cell Lung Cancer - Pipeline by BioAtla LLC, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Biocad, H1 2018
Non-Small Cell Lung Cancer - Pipeline by BioCancell Ltd, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Biocon Ltd, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2018
Non-Small Cell Lung Cancer - Pipeline by BioLineRx Ltd, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Biothera Pharmaceutical Inc, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Blueprint Medicines Corp, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Boston Biomedical Inc, H1 2018
Non-Small Cell Lung Cancer - Pipeline by BriaCell Therapeutics Corp, H1 2018
Non-Small Cell Lung Cancer - Pipeline by BrightPath Biotherapeutics Co Ltd, H1 2018
Non-Small Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Co, H1 2018
List of Figures
Number of Products under Development for Non-Small Cell Lung Cancer, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Top 10 Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report